ArticleAsian Pacific journal of cancer prevention : APJCP2026
Towards Precision Oncology: A Predictive Nomogram Incorporating DPD and MTHFR for CapeOX Neoadjuvant Chemotherapy in Colorectal Cancer.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is one of the most prevalent malignancies worldwide. Variability in patient response to fluoropyrimidine-based neoadjuvant chemotherapy remains a critical challenge. We aimed to develop a nomogram that integrated dihydropyrimidine dehydrogenase (DPD) and methylenetetrahydrofolate reductase (MTHFR) expression to predict CapeOX (Capecitabine-Oxaliplatin) neoadjuvant chemotherapy outcomes in colorectal cancer.
methodsA prospective cohort of 36 advanced-stage CRC patients who received CapeOX neoadjuvant chemotherapy at Wahidin Sudirohusodo Hospital from 2024 to 2025 was analyzed. mRNA expression levels of TS, DPD, and MTHFR were measured in tissue and blood using quantitative RT-PCR. The chemotherapy response was evaluated by RECIST 1.1. Statistical analysis was performed to identify predictors of response, which were incorporated into a nomogram with bootstrap validation.
resultsAmong the 36 patients with advanced colorectal cancer, response to CapeOX chemotherapy was observed in 50%. Blood-based gene profiling revealed that responders had significantly lower DPD and MTHFR expression compared with non-responders (both p<0.001), while TS showed no predictive relevance. A nomogram that integrated only blood DPD and MTHFR achieved outstanding discrimination (AUC 0.932, C-index 0.78) and demonstrated strong calibration, accurately predicting treatment response across probability ranges. These results established circulating DPD and MTHFR as powerful non-invasive biomarkers and validated the nomogram as a robust tool for individualized response prediction.
conclusionA predictive nomogram that incorporated DPD and MTHFR has improved individualized estimation of CapeOX neoadjuvant chemotherapy response in CRC, supporting precision oncology strategies.<br />.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.